I. Indications and contraindications for interventional treatment Indications for hepatic artery embolization for hepatic hemangioma treatment: those with symptoms, those with ruptured and bleeding hepatic hemangioma, those with masses larger than 5 cm in diameter, those with tumor tendency to increase in size or those with masses located under the liver envelope that are likely to rupture under external force. Overall, regardless of the site, scope and number, there is no absolute contraindication to hepatic artery embolization for the treatment of hepatic hemangioma, but it is used with caution in severe liver and kidney insufficiency. The main blood supply of hepatic hemangioma comes from hepatic artery, and portal vein basically does not participate in blood supply (rarely seen as portal vein blood supply), which is the theoretical basis of hepatic artery embolization for the treatment of hepatic hemangioma. The specific method of hepatic hemangioma intervention is to use percutaneous puncture, often by inserting a catheter into the hepatic artery from within the femoral artery. Hepatic arteriogram is performed first, and then according to the image, the blood supply artery of hepatic hemangioma is confirmed, and the catheter is super-selectively inserted into the target vessel of the tumor, and appropriate amount of drugs and embolic agents are injected to perform sclerotherapy embolization. The commonly used embolic drugs include pinyamycin and iodinated oil emulsion, gelatin sponge, etc. After the operation, there may be hypothermia, local discomfort and nausea and other reactions, which usually can return to normal after 3 days. The embolic agent injected by interventional therapy enters and stays in these blood sinuses, causing the destruction of endothelial cells of hemangioma blood sinuses, thrombus formation and permanent occlusion of blood sinuses. The tumor will then shrink or disappear and will not rupture and bleed, achieving a therapeutic effect. We have successfully performed several cases of interventional treatment for hepatic cavernous hemangioma without a single complication, and the tumors all shrank significantly from 3 to 6 months after treatment, and about 40% of patients had their tumors completely disappeared after one year. In one female patient, the maximum diameter of hepatic hemangioma was 24 cm, and the abdomen was obviously enlarged, and the maximum diameter was 16 cm at 9 months after the first intervention, and the maximum diameter was 10 cm at 12 months after the second intervention, and the abdominal enlargement was nearly disappeared. Therefore, transhepatic artery embolization has become the main treatment method for hepatic hemangioma because it is less traumatic, faster recovery (usually about one week of hospitalization), lower cost than surgical operation, better efficacy and lower complications.